RegMed Forum 2017 - Advanced Disease Models
In regenerative medicine, the efficient development of new therapy options, such as cell therapies, requires suitable in-vitro disease model systems beyond the current standard. Innovative 3D cell culture approaches, 3D bioprinting and organ-on-a-chip model systems have all seen tremendous progress over the last decade. Now, even multi-organ-on-a-chip models are within reach. All these systems are reproducing in-vivo conditions of human health and disease in unprecedented ways.
The Berlin-Brandenburg Center for Regenerative Therapies (BCRT) and Berlin Partner are jointly organising the RegMed Forum 2017 on December, 6th 2017 in Berlin, Germany. This year, the international conference will focus on how the combination of technology and disease modelling can achieve physiologically relevant results and, ultimately, clinical impact.
Together, stakeholders from industry and academia will explore the following topics:
- 3D cell culture
- 3D bioprinting
- organ and human-on-a-chip models
Confirmed Speakers (as of June 2017):
Michael Shuler, Cornell University, USA
- Olivier Frey, InSphero AG, Switzerland
- N.N., Organovo, USA
- Bruno Brisson, Poietis, France
- Reyk Horland, TissUse GmbH, Germany
Murat Cirit, MIT, USA
Marcel Karperien, University of Twente, Netherlands
- Lutz Kloke, Cellbricks GmbH, Germany
- Christian Regenbrecht, cpo GmbH, Germany
- Colin J. Wilde, AvantiCell, UK
Heike Walles, Fraunhofer IGB, Germany
Andreas Kurtz, BCRT, Germany
What can you expect?
Conference program about recent trends in advanced disease modeling and regenerative medicine
Who will be attending?
The conference attracts about 120 international delegates from clinics, biotech and pharma industry as well as research institutions looking for co-development or joint research opportunities. Join our event and find partners to drive your business successfully forward!
We look forward to meeting you in Berlin!
About the Event
We cordially invite you to participate and discuss the latest trends and innovative technologies in disease modeling with stakeholders from academia and industry at the “RegMed Forum 2017 – Advanced Disease Models”. This scientific event is co-organized by the BCRT and the Cluster HealthCapital Berlin-Brandenburg - this year in cooperation with TissUse, Cellbricks, cpo and the German Stem Cell Network (GSCN).
The “RegMed Forum 2017 – Advanced Disease Models” provides the opportunity to network with important actors along the value chain and supports transferring innovations from basic research into clinics and industry. In addition to a comprehensive scientific program with presentations from local research groups, international guests from academia and industry, there will be plenty of opportunities for industry and research groups to present their field of activities and to network in the industry exhibition.
About Berlin Brandenburg Center for Regenerative Therapies (BCRT)
The research landscape of Berlin/Brandenburg has developed into one of the most important international clusters for Regenerative Medicine. A major contribution to this development has been the Berlin-Brandenburg Center for Regenerative Therapies (BCRT), which was established 11 years ago. The BCRT is an interdisciplinary clinical translational center jointly operated by Charité Universitaetsmedizin Berlin and Helmholtz-Zentrum Geesthacht (with its site in Teltow).
The BCRT’s focus lies on the concept of endogenous regeneration, which is realized by using cells, biomaterials, factors and the combination thereof, and addresses primarily diseases of the immune system, the musculoskeletal system and the cardiovascular system. First fruits of success with regard to the development and implementation of innovative therapies and products from BCRT are, e.g., virus-specific T-cell products for long-term protection against serious infections, which particularly affect patients with a weakened immune system. They are now evaluated in clinical studies on site. Following the concept of refined translation, i.e. iterative incorporation of (pre-)clinical research findings into product development, and the use of biomarkers, the BCRT is actively pushing further treatment concepts towards a clinical evaluation. This includes new cell-based approaches for heart disease and muscle injuries as well as new polymer-based devices like cardiovascular implants and systems for soft tissue regeneration or drug release. Such approaches may give rise to an enormous worldwide commercial potential, as the commercialization of Regenerative Medicine has just begun.
Funded by the federal state of Berlin, the federal state of Brandenburg and the Investitionsbank Berlin, co-funded by the European Union (European Fund for Regional Development).